Progressive Supranuclear Palsy (PSP)
Neurology·MeSH: Supranuclear Palsy, Progressive
Prevalence
5.0 / 100K
1 drug in development·1 company·2 clinical trials
Drug Pipeline by Phase
Phase 2(1)
| Drug | Company |
|---|---|
| ARV-102 | ARVINAS, INC. (ARVN) |
Frequently asked questions
How many drugs are in development for Progressive Supranuclear Palsy (PSP)?
BioSniper tracks 1 drug in development for Progressive Supranuclear Palsy (PSP) across 1 company.
How many clinical trials target Progressive Supranuclear Palsy (PSP)?
There are 2 clinical trials targeting Progressive Supranuclear Palsy (PSP) tracked by BioSniper.
What is the prevalence of Progressive Supranuclear Palsy (PSP)?
The estimated prevalence of Progressive Supranuclear Palsy (PSP) is approximately 5.0 per 100,000 population.
Deep-dive into Progressive Supranuclear Palsy (PSP)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis